Aims: To develop and evaluate the performance of a panel of isothermal realtime recombinase polymerase amplification (RPA) assays for detection of common bacterial urinary tract infection (UTI) pathogens. Methods and Results: The panel included RPAs for Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa and Enterococcus faecalis. All five RPAs required reaction times of under 12 min to reach their lower limit of detection of 100 genomes per reaction or less, and did not cross-react with high concentrations of nontarget bacterial genomic DNA. In a 50-sample retrospective clinical study, the five-RPA assay panel was found to have a specificity of 100% (95% CI, 78-100%) and a sensitivity of 89% (95% CI, 75-96%) for UTI detection.
Introduction
Urinary tract infections (UTIs) annually affect 150 million people worldwide, and accounted for an estimated 10Á5 million office visits and 2-3 million emergency department visits in the United States in 2007 (Stamm and Norrby 2001; Niska et al. 2010; Schappert and Rechtsteiner 2011) UTIs, which can be symptomatic or asymptomatic, are a notable cause of morbidity in infant or elderly males, and females of all ages (Foxman 2010) . Sequelae range in severity from frequent recurrences to renal scarring and life-threatening sepsis (Foxman 2002) . For most UTIs, antibiotics are the most recommended and effective treatment option following diagnosis (Foxman 2010) .
The diagnosis of UTIs is currently based on clinical symptoms, nonculture methods, such as dipstick tests for nitrites or leucocyte esterase activity, and pathogen detection/identification by the gold standard urine culture method. Clinical symptoms overlap with other noninfectious conditions and therefore have poor specificity, while dipstick tests, which do not identify pathogens, are known to have poor positive predictive values despite being useful to rule out infections (Zaman et al. 1998; Semeniuk and Church 1999; Devill e et al. 2004) . Urine cultures, while mostly accurate, can take up to 72 h to provide a result. Consequently, initial UTI treatments are mostly empirical and broad spectrum in nature with the goal of reducing the duration of patient discomfort. This widespread, injudicious use of antibiotics has accelerated the emergence of multidrug-resistant UTI pathogens . It is clear that methods for rapid UTI pathogen detection and identification at the point-of-care or in a clinical laboratory could help avoid imprecise treatments, and thereby have a positive impact on UTI management.
There is an increased interest in developing rapid UTI diagnostics to supplement or replace urine cultures. Various assays based on electrochemical biosensing, mass spectrometry, microcalorimetry, Raman spectroscopy and real-time PCR have been recently reported (Liao et al. 2006; Lehmann et al. 2010 Lehmann et al. , 2011 Bonkat et al. 2012; Kloß et al. 2013; Wang et al. 2013; Burillo et al. 2014) . Among these, real-time PCR and other nucleic acid amplification techniques (NAATs) are already well-established in clinical diagnostics, and have recently been developed into automated multiplex-capable platforms suitable for use in near-patient settings (Tang et al. 1997; Raja et al. 2005; Poritz et al. 2011) . Isothermal NAATs, which offer performance comparable to PCR and a much faster time-to-result in many cases, are more amenable to low complexity, small-footprint devices due to the lack of thermal cycling requirements (Gill and Ghaemi 2008; Asiello and Baeumner 2011; Kim and Easley 2011; Niemz et al. 2011; Craw and Balachandran 2012) . Of the DNAspecific isothermal NAATs, recombinase polymerase amplification (RPA) stands out by virtue of being the least complex to design and optimize, and the fastest-to-result.
Recombinase polymerase amplification uses T4 phage recombinases UvsX and UvsY to facilitate the site-specific strand invasion of 30-35 nt primers into a DNA template, following which the strand-displacing Sau polymerase (Staphylococcus aureus) mediates primer extension; the cyclic repetition of this process at a constant temperature of 37-42°C yields dsDNA amplicons exponentially as in PCR. In end-point RPA, agarose gel electrophoresis is used to visualize amplified DNA after 20-30 min. In realtime RPA, recombinases facilitate the hybridization of 46-52-nt-long TwistAmp exo probes to either the positive-or negative-sense strand of the target amplicon. TwistAmp exo probes are oligonucleotides carrying a fluorophore and quencher separated by an abasic nucleotide analog (tetrahydrofuran, THF) located approximately 15 nt upstream of the 3 0 end. Following target hybridization, the double-strand-specific Escherichia coli exonuclease III recognizes and cleaves the THF site, releasing the quencher and resulting in the amplification-dependent development of fluorescence (Piepenburg et al. 2006) .
In this paper, we describe the development of a panel of highly sensitive and specific exo probe-based real-time RPA assays for the detection of five bacterial pathogens that are among the most commonly implicated aetiologic agents of UTIs. These pathogens-E. coli, Proteus mirabilis, Klebsiella pneumoniae, Pseudomonas aeruginosa and Enterococcus spp.-were collectively detected in 84% and 85% of North American and European UTI samples, respectively, in the SENTRY Antimicrobial Surveillance Program (Jones et al. 1999; Fluit et al. 2000) ; they could be more or less frequent in specific patient populations. All five real-time RPA assays were able to detect 100 genomes per reaction or less, and showed no cross-reactivity with high concentrations of nontarget genomic DNA. In a pilot retrospective study for clinical evaluation, the assay panel was found to have a specificity of 100% (95% CI, 78-100%) and a sensitivity of 89% (95% CI, 75-96%) for the detection of a UTI.
Materials and methods

Quantitative genomic DNA standards
For analytical sensitivity and specificity determination, standards were generated by isolation and purification of genomic DNA (gDNA) from bacterial colonies grown on culture plates. Recombinase polymerase amplification primers were designed to be between 30 and 35 nt long (for optimal recombinase activity), with GC content between 30 and 70% and either a G or a C at the 3 0 end to provide a more stably clamped target for the polymerase. Sequence elements likely to contribute to hairpin-like secondary structures or primer-primer interactions were avoided. For each target gene, two or three sets of forward and reverse primers were designed to overlap a 150-250-bp conserved region in a staggered manner. To lower the possibility of nonspecifically amplifying human DNA or unrelated UTI pathogens, the sequence specificity of all designed primers was evaluated by performing a BLAST search against publicly available nucleotide sequences of the following species: Homo sapiens, E. coli, P. mirabilis, K. pneumoniae, P. aeruginosa, Enterococcus faecalis, Enterococcus faecium, Citrobacter freundii, Enterobacter cloacae, Acinetobacter baumannii, S. aureus, Providencia rettgeri, Providencia stuartii, Morganella morganii and Streptococcus agalactiae. Primers that had less than six overall mismatches to a nontarget sequence and/or less than four mismatches to a nontarget sequence in the last six nucleotides at the 3 0 end were rejected. Primers were purchased from Integrated DNA Technologies (Coralville, IA).
For verification of RPA product specificity, and to aid exo probe design, the outermost primers designed for each target gene were used in end-point RPA using purified gDNA as the template, followed by Sanger sequencing of the amplification product. End-point RPA was performed in a 50-ll volume using TwistAmp Basic kits (TwistDx, Cambridge, UK). Master mixes containing 480 nmol l À1 RPA primers and TwistAmp rehydration buffer were prepared and distributed, in 42Á5 ll volumes, into 0Á2-ml reaction tubes containing dried enzyme pellets. The enzyme pellet in each tube was rapidly solubilized by pipetting the master mix up and down upon addition. Subsequently, 5 ll of template was added to the tubes. Magnesium acetate (2Á5 ll) (bringing the concentration of Mg 2+ to 14 mmol l À1 ) was then pipetted into the tube lids, centrifuged into the tubes using a mini centrifuge and immediately placed into a PCR thermal cycler (Bio-Rad Laboratories, Hercules, CA) programmed to operate at 42°C for 30 min. RPA products were purified using a PCR purification kit (Qiagen, Valencia, CA) and bi-directionally Sanger-sequenced (SeqWright, Houston, TX). Sanger sequencing results were used to confirm amplicon size and homology to GenBank sequences at a single-nucleotide level. Using these sequences, TwistAmp exo probes (46-52 nt) were designed to be homologous to the positive-or negative-sense strands of the target regions flanked by the primers, and not to overlap with the primers themselves. All probes (synthesized by LGC Biosearch Technologies) contained a dT-FAM (thymine labelled with 6-carboxyfluorescein) and a dT-BHQ1 (thymine labelled with Black Hole Quencher â -1, which quenches FAM in close proximity) separated by a THF cleavable linker; they also contained a three carbon spacer at the 3 0 end to block polymerase-mediated extension. OligoAnalyzer was used to analyse secondary structures and their free energies.
Real-time RPA experiments and data analysis
Real-time RPA reactions were performed in 50-ll volumes using TwistAmp exo kits (TwistDx, Cambridge, UK). Master mixes containing 420 nmol l À1 RPA primers, 120 nmol l À1 RPA exo probes and Twist Amp rehydration buffer were prepared and distributed, in 42Á5 ll volumes, into reaction tubes supplied with dried enzyme pellets. Five microlitres of template (quantitative gDNA standards or total DNA from clinical sample) was then added to the tubes. The 5-ll aliquot has been optimized for detecting between 10 2 to 10 6 CFU per ml in urine. To start the reaction, 2Á5 ll of magnesium acetate was added to each tube (to bring the total Mg 2+ concentration to 14 mmol l À1 ) by pipetting into tube lids and centrifuging immediately before placing the tubes in an Agilent MxPro 3005 real-time PCR machine (Agilent Technologies, Santa Clara, CA). The real-time PCR machine was programmed to run for 20 min at 42°C and collect fluorescence data at 10-s intervals. Fluorescence data from real-time RPA assays using different exo probes was normalized (subtraction of baseline function from raw fluorescence) and thresholded individually, using MxPro software (Agilent Technologies). Baseline functions for each probe were calculated by fitting the raw fluorescence data obtained between 2 and 3 min from the beginning of the reaction to a line using a linear least mean squares algorithm. This baseline function was subtracted from the raw fluorescence (R) function to obtain baseline-corrected fluorescence (dR). A 9-point moving average was applied to smooth the amplification curve that plotted baseline-corrected fluorescence (dR) against time. Threshold times (analogous to threshold cycles in real-time PCR) represented the times, from the beginning of reactions, at which the baseline-corrected fluorescence exceeded a threshold value located in the exponential growth regions of amplification curves. Threshold values of dR were empirically set to be between 25 and 100 standard deviations above background fluorescence for each exo probe, and used consistently thereafter.
Determination of analytical sensitivity and specificity
The analytical sensitivities (limits of detection) of the panel of real-time RPA assays were estimated by performing real-time RPA on three to six replicates of different 10-fold serial dilutions of the quantitative gDNA standards, from 10 7 genome copies per reaction down to 10 genome copies per reaction. The threshold time was plotted against genome copies detected, and a semi-log regression was calculated. For analytical specificity determination, each assay on the panel was performed in triplicate using 10 6 genome copies of nontarget gDNA, from each other pathogen on the panel individually, as the template.
Clinical evaluation of RPA panel
The panel of the 5-RPA assays was clinically evaluated using 50 randomly selected clinical urine samples (from 50 unique patients) from among those collected by Medical Center Laboratories in Houston, Texas, between 5 August and 18 August 2014. These samples were collected from symptomatic and asymptomatic in-and outpatients in the Greater Houston area. The median age of the patients was 80Á5 years (range 13-104 years); 70% of the patients were female. 'Gold standard' comparison results were obtained by urine culture. Briefly, urine specimens were first inoculated on 5% sheep blood agar plates (Becton, Dickinson and Company) using an InfoLab 1-ll calibrated loop. Following aerobic incubation at 37°C for 12, 24 or 48 h, a VITEK â 2 system (bioM erieux, Marcy l'Etoile, France) was used according to the manufacturer's instructions to establish pathogen identity in what were considered 'true positive' samples-culture-positive plates with more than 10 colonies, indicating the presence of >10 4 CFU per ml urine. If multiple pathogens were present, all pathogens were identified and reported.
Total DNA was extracted from clinical urine samples (within 12 h of collection) using a simple, high-throughput method (Lu et al. 2011) . Briefly, 1 ml urine was pipetted into a 1Á5 ml microcentrifuge tube and centrifuged at 12 000 g for 5 min. The supernatant was discarded and 100 ll lysis buffer (1% Tween-20, 1% NP-40, 0Á03% SDS, 5% Chelex 100 and 400 lg ml À1 proteinase K) was added to the pellet and thoroughly mixed. The mixture was incubated at 56°C for 1 h, followed by 100°C for 10 min. The lysate was then centrifuged at 13 000 g for 5 min, and 50 ll of the supernatant was aliquoted and stored at À20°C. The University of Houston's Committee for the Protection of Human Subjects approved an application (no. 4228-14209) to exempt the RPA analysis of these samples from Institutional Review Board approval due to their de-identified nature. To test each clinical sample against the UTI RPA panel being evaluated, 5 ll of lysate supernatant was used as the template in five separate real-time RPA assays. Fluorescence data from the five tubes for each sample were normalized and thresholded as described above. A threshold time of less than 15 min in at least one reaction tube indicated a 'positive' result, while no amplification above the threshold in all five tubes indicated a 'negative' result. Sensitivity and specificity were calculated using the number of true positives (TP), false negatives (FN), false positives (FP) and false negatives (FN) as follows: Sensitivity = (TP)/(TP + FN); Specificity = (TN)/(TN + FP). Confidence intervals were calculated using the widely used Wilson score method (Wilson 1927) .
Results
RPA primer and probe design
The following species-specific target genes were used for amplicon design: chuA for E. coli, khe for K. pneumoniae, lasB for P. aeruginosa, ureR for P. mirabilis and rpoA for Enterococcus spp. (Clermont et al. 2000; Naser et al. 2005; Shi et al. 2012; Zhang et al. 2013; Braun et al. 2014) . The most challenging primer and probe design was that for Enterococcus. Although 12 Enterococcus species have been identified as being pathogenic to humans, E. faecalis and E. faecium account for approximately 85-90% and 5-10% of clinical enterococcal isolates respectively (Murray 1990 (Murray , 2000 Gin and Zhanel 1996; Gold 2001; Zhanel et al. 2003) . Several candidate genes including atpD, phoE, ddl, rpoB, tuf and rpoA were initially evaluated for RPA amplicon-appropriate conserved regions between E. faecalis and E. faecium (preliminary probe/primer design for Enterococcus spp not shown). rpoA was chosen because it had the least evenly spread mismatches between the enterococcal species; it also resulted in the most sequence-specific primers. For each pathogen on the panel, between six and nine primer pairs were screened for optimal performance using real-time RPA with quantitative gDNA standards as the template. Primer pairs that resulted in the shortest threshold times for the lowest concentration of gDNA were selected. Final amplicon lengths ranged from 161 to 211 bp, as shown in Table 1 . Primer and probe sequences are indicated in Table 2 .
RPA analytical sensitivity and specificity
Quantitative gDNA standards from reference strains were used to test the analytical sensitivities of all five real-time RPA assays. Three replicates were tested for gDNA concentrations ≥1000 genome copies per reaction, while six replicates were tested for 10 and 100 genome copies per reaction. Threshold times were plotted against gDNA concentrations and fit to a semi-log regression line (Fig. 1) . All replicates tested positive at gDNA concentrations ≥100 genome copies per reaction. Replicates for gDNA concentrations of 10 genomes copies per reaction for E. coli, E. faecalis, P. mirabilis and P. aeruginosa were positive in 3/6, 5/6, 4/6 and 4/6 cases, respectively, putting the analytical sensitivity of those assays between 10 and 100 genome copies per reaction. All 6 replicates of the 10 genome copies per reaction sample were negative for the K. pneumoniae assay, putting its analytical sensitivity between 100 and 1000 genomes copies per reaction. Average threshold times for the lowest gDNA concentration detected by assays for E. coli, E. faecalis, P. mirabilis, P. aeruginosa and K. pneumoniae were 9Á5, 9Á4, 8Á6, 10Á5 and 11Á5 min respectively.
The analytical specificity of all RPAs was determined by cross-testing each primer/probe set against 10 6 genome copies per reaction of each panel UTI pathogen separately, that is, E. coli (ATCC 35218), P. aeruginosa (ATCC 27853), K. pneumoniae (ATCC 700603), E. faecalis (ATCC 29212) and P. mirabilis (ATCC 25933). Only specific detection was observed; amplification curves for all nonspecific reactions did not exceed threshold dR values during the 20 min reaction time.
Clinical evaluation of UTI RPA panel
In total, 50 urine samples were included in the study, with 36 true positives (72%) and 14 true negatives (28%) as determined by urine culture for pathogen detection and VITEK 2 for pathogen identification. Of the 36 culture-positive plates analysed by VITEK 2, 26 had 
monomicrobial growth, 9 had bimicrobial growth and 1 had trimicrobial growth, with the identities of all pathogens reported. Total DNA was extracted from 1 ml of all 50 samples by the method described in the Materials and methods section, following which 5 ll of extracted DNA from each sample (equivalent to 50 ll of urine) was used as the amplification template for RPA reactions targeting each of the five pathogens. Four of 36 culture-positive samples returned negative results from all five RPA reactions, and were considered false negatives. One of four false negatives was a M. morganii infection (not covered by the panel), while the others were samples containing E. coli, P. mirabilis and K. pneumoniae. Thirty-two of 36 culture-positive samples returned at least one positive RPA reaction. Fourteen of 14 culture-negative samples returned negative results from all five RPA reactions. Based on these results, the overall clinical sensitivity and specificity for the detection of a UTI by the RPA panel can be estimated at 89% (95% CI, 75-96%) and 100% (95% CI, 78-100%) respectively (Table 3) . Diagnostic accuracy analyses were also performed at a species-specific level. Among the pathogens included in the RPA panel, E. coli was the most commonly identified (n = 14), followed by P. mirabilis (n = 12), Enterococcus spp. and K. pneumoniae (n = 5), and P. aeruginosa (n = 2). Three pathogens not included in the RPA panel (M. morganii, S. aureus and Group B Streptococcus) were identified by VITEK 2 in one monomicrobial sample and four polymicrobial samples. Table 4 shows the speciesspecific true-and false-positive and -negative results, sensitivities and specificities for each pathogen covered by the panel.
Discussion
Culture-based detection and identification of UTI-causing pathogens is responsible for up to 40% of the workload of clinical microbiology laboratories (Wilson and Gaido 2004) . While it can be argued that cultures provide greater diagnostic reliability compared to dipstick methods, the 24-to 72-h time span before the availability of culture results means they may have little impact on initial antibiotic therapy of 72-h duration, which ends up being empirical and potentially inappropriate (Burd and Kehl 2011) . Point-of-care testing panels for rapid identification of pathogens and/or antibiotic susceptibility-with assay targets determined by the setting (in-patient/outpatient), patient population (first-episode vs recurrent infection, paediatric vs adult, etc.) or severity (complicated vs uncomplicated infection)-could therefore contribute significantly to lowering the clinical and economic burden of UTIs. In this study, we developed a panel of real-time RPA assays for five of the most common bacterial UTI pathogens, and evaluated it in a small clinical study. We chose RPA over other isothermal NAATs such as loop-mediated isothermal amplification (LAMP) and helicase-dependent amplification (HDA) for the following reasons: faster enzyme kinetics for DNA amplification to a detectable level at low target concentrations-10 min for RPA compared to 30-60 min for LAMP and HDA (Hill et al. 2008; ; easier oligonucleotide design, with only three conserved regions required; easy availability of lyophilized reagents not requiring cold chain storage (Crannell et al. 2014b) ; and ease of implementation in point-of-care-friendly devices and formats -examples include the ESEquant Tubescanner system, the lateral flow assay and digital and centrifugal microfluidic platforms (Lutz et al. 2010; Euler et al. 2012; Kim et al. 2014; Crannell et al. 2015a; Kalsi et al. 2015) . These advantages have made RPA a popular choice for infectious disease diagnostics, including assays for K. pneumoniae, Category A bioterrorism agents, Group B streptococci, Chlamydia trachomatis, HIV and Cryptosporidium spp. (Rohrman and Richards-Kortum 2012; Euler et al. 2013; Crannell et al. 2014a; Daher et al. 2014; Krolov et al. 2014; Valiadi et al. 2016) . To the best of our knowledge, this is the first report on the development a panel of RPA assays specifically targeting UTI pathogens.
With regard to analytical sensitivity and specificity, the RPAs developed demonstrated limits of detection comparable to other RPAs for DNA amplification in the published literature (10-100 or 100-1000 molecules per reaction), and showed no cross-detection among the targets on the panel. The assays achieved their detection limits much faster than PCR or other isothermal NAATs, emphasizing the rapid reaction kinetics of the DNA polymerase and exonuclease enzymes used. The design of oligonucleotides for real-time RPA is as flexible as probebased real-time PCR, with only three conserved regions required, as opposed to other isothermal NAATs like LAMP that require four to six primers. However, the long required length of the exo probe is a potential impediment to rapid design, especially for RPAs targeting multiple species with relatively low sequence homology. Longer oligonucleotides also make undesirable secondary structures with highly negative free energies much more likely, potentially affecting assay performance. The exo probe targeting K. pneumoniae, for example, was predicted to have a secondary structure (DG = À3Á52 kcal mol À1 ) that creates a double-stranded neighbourhood around the nucleotide to be replaced by exonuclease-cleavable THF (Fig. 2) . This likely resulted in the assay for K. pneumoniae having a higher background fluorescence (data not shown) and worse analytical sensitivity compared to other assays on the panel.
In a retrospective clinical study using 50 urine samples of patients suspected of having UTIs, our panel of realtime RPA assays was determined to have a sensitivity and specificity of 89% (95% CI, 75-96%) and 100% (95% CI, 78-100%), respectively, for UTI detection. A number of the urine-derived samples tested by the RPA panel could be expected to have had a high concentration of human DNA (due to pyuria) and DNA from nonpathogenic microbes (skin flora). High background DNA has been shown to lower RPA sensitivity, and might have been responsible for the false negative results among pathogens included on the panel (Rohrman and Richards-Kortum 2015) . Another potential cause of the false negatives is the inhibitory effect of detergents on RPA enzymes, which can be overcome by adapting a different approach for sample preparation; for example, heating urine at 90°C for 5 min has been shown to be effective in releasing pathogen DNA (Krolov et al. 2014) .
It should be noted that we used a cut-off of ≥10 000 CFU per ml of urine, as determined by colony counting on a culture plate, to designate a urine sample as being UTI-positive (Wilson and Gaido 2004) . Our current sample preparation method, in which total DNA from 50 ll of urine was used as the template for each RPA reaction, was optimized for this cut-off. Lower and higher cut-offs in the range of 10 2 -10 6 CFU per ml are recommended for specific patient populations (Stark and Maki 1984; Coulthard et al. 2010; Hooton et al. 2010) . To avoid potential false positives and false negatives caused by testing samples outside the cut-off range sample preparation protocol would need to be modified to ensure greater enrichment (for cut-offs <10 4 CFU per ml) or dilution (for cut-offs >10 4 CFU per ml) of total urine-derived DNA per reaction. Semi-quantitative RPA, based on threshold time cut-off (analogous to semiquantitative PCR), or fully quantitative RPA, based on internal positive controls, could be used to supplement alternate sample preparation methods (Hansen et al. 2013; Crannell et al. 2014c Crannell et al. , 2015b .
The accurate definition of an assay is imperative to ensure its clinical relevance. The panel of assays defined in this study covered a majority of the pathogens in the clinical samples tested; however, the samples included in the study were only representative of the predominantly geriatric patient population served by a single clinical microbiology laboratory in Houston. The aetiology of UTIs can vary significantly by geography and patient age (Kahlmeter 2000; Langley et al. 2001) . The healthcare setting from which the sample originates is also important -the higher propensity for complicated UTIs in inpatient settings like hospitals or assisted-living facilities such as nursing homes results in significantly different distributions of causative bacteria compared to ambulatory and outpatient settings (Wilson and Gaido 2004; Laupland et al. 2007; Flores-Mireles et al. 2015) . Our choice of pathogens might therefore not be optimal for other patient populations.
In summary, we have demonstrated the analytical and clinical validity of a panel of very rapid and highly sensitive real-time RPAs for the isothermal detection of common UTI pathogens. The ease of developing RPA assays, along with the plethora of formats available for easy implementation, make it an excellent tool to develop a highly tailored panel of assays that target UTI pathogens and/or common antibiotic susceptibility genes. The routine and widespread use of RPA to supplement or replace culture-based methods could profoundly impact UTI management and the emergence of multidrug-resistant pathogens by obviating empirical broad-spectrum therapies.
